Denali Therapeutics (DNLI) Stock Forecast, Price & News

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last twelve months. There are currently 12 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DNLI shares.
View DNLI analyst ratings or view top-rated stocks.

12 equities research analysts have issued twelve-month target prices for Denali Therapeutics' shares. Their DNLI share price forecasts range from $30.00 to $105.00. On average, they anticipate the company's stock price to reach $52.09 in the next year. This suggests a possible upside of 67.7% from the stock's current price.
View analysts price targets for DNLI or view top-rated stocks among Wall Street analysts.

Denali Therapeutics' stock was trading at $27.81 at the beginning of the year. Since then, DNLI stock has increased by 11.7% and is now trading at $31.07.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our DNLI earnings forecast.

Denali Therapeutics Inc. (NASDAQ:DNLI) issued its earnings results on Monday, May, 8th. The company reported ($0.80) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by $0.10. The firm had revenue of $35.14 million for the quarter, compared to analyst estimates of $29.88 million. Denali Therapeutics had a negative net margin of 365.21% and a negative trailing twelve-month return on equity of 40.01%. The company's quarterly revenue was down 16.6% on a year-over-year basis. During the same period last year, the firm earned ($0.53) earnings per share.

ETFs with the largest weight of Denali Therapeutics (NASDAQ:DNLI) stock in their portfolio include ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU), iShares Biotechnology ETF (IBB), Global X Aging Population ETF (AGNG) and Invesco Nasdaq Biotechnology ETF (IBBQ).

1 employees have rated Denali Therapeutics Chief Executive Officer Ryan Watts on Glassdoor.com. Ryan Watts has an approval rating of 100% among the company's employees. This puts Ryan Watts in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Denali Therapeutics investors own include Progenics Pharmaceuticals (PGNX), Editas Medicine (EDIT), Intellia Therapeutics (NTLA), Sangamo Therapeutics (SGMO), Kratos Defense & Security Solutions (KTOS), CRISPR Therapeutics (CRSP), Anavex Life Sciences (AVXL), NVIDIA (NVDA), Invitae (NVTA) and Pretium Resources (PVG).

(DNLI) raised $149 million in an initial public offering on Friday, December 8th 2017. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Evercore ISI was co-manager.

Denali Therapeutics trades on the NASDAQ under the ticker symbol "DNLI."

Denali Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Baillie Gifford & Co. (11.23%), BlackRock Inc. (6.93%), Temasek Holdings Private Ltd (5.04%), Wellington Management Group LLP (3.80%), State Street Corp (3.35%) and Price T Rowe Associates Inc. MD (2.58%). Insiders that own company stock include Alexander O Schuth, Alexander O Schuth, Carole Ho, David P Schenkein, David P Schenkein, Douglas K Bratton, Marc Tessier-Lavigne, Ryan J Watts, Ryan J Watts, Steve E Krognes, Steve E Krognes, Vicki L Sato and Vicki L Sato.
View institutional ownership trends.

Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DNLI stock can currently be purchased for approximately $31.07.

Denali Therapeutics (NASDAQ:DNLI) has a market capitalization of $4.25 billion and generates $101.46 million in revenue each year. The company earns $-325,990,000.00 in net income (profit) each year or ($2.87) on an earnings per share basis.

The company employs 380 workers across the globe.

Denali Therapeutics' mailing address is 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.denalitherapeutics.com. The company can be reached via phone at (615) 866-8548 or via email at hansen@dnli.com.